Cite
Growth differentiation factor-15 is not modified by sacubitril/valsartan and is an independent marker of risk in patients with heart failure and reduced ejection fraction: the PARADIGM-HF trial.
MLA
Bouabdallaoui, Nadia, et al. “Growth Differentiation Factor-15 Is Not Modified by Sacubitril/Valsartan and Is an Independent Marker of Risk in Patients with Heart Failure and Reduced Ejection Fraction: The PARADIGM-HF Trial.” European Journal of Heart Failure, vol. 20, no. 12, Dec. 2018, pp. 1701–09. EBSCOhost, https://doi.org/10.1002/ejhf.1301.
APA
Bouabdallaoui, N., Claggett, B., Zile, M. R., McMurray, J. J. V., O’Meara, E., Packer, M., Prescott, M. F., Swedberg, K., Solomon, S. D., Rouleau, J. L., & PARADIGM-HF Investigators and Committees. (2018). Growth differentiation factor-15 is not modified by sacubitril/valsartan and is an independent marker of risk in patients with heart failure and reduced ejection fraction: the PARADIGM-HF trial. European Journal of Heart Failure, 20(12), 1701–1709. https://doi.org/10.1002/ejhf.1301
Chicago
Bouabdallaoui, Nadia, Brian Claggett, Michael R. Zile, John J.V. McMurray, Eileen O’Meara, Milton Packer, Margarett F. Prescott, et al. 2018. “Growth Differentiation Factor-15 Is Not Modified by Sacubitril/Valsartan and Is an Independent Marker of Risk in Patients with Heart Failure and Reduced Ejection Fraction: The PARADIGM-HF Trial.” European Journal of Heart Failure 20 (12): 1701–9. doi:10.1002/ejhf.1301.